Умеренные когнитивные расстройства: некоторые патогенетические, клинические и терапевтические аспекты

1. Андреев Н.А., Моисеев В.С. Антагонисты кальция в клинической
медицине. М.: РЦ «Фармединфо», 1995.
2. Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом
и старческом возрасте. Метод. пособ. для врачей. М., 2005.
3. Козловский В.Л. Влияние блокаторов кальциевых каналов на
эффективность галоперидола и фенамина у мышей и крыс.
Эксп. клин фармакол. 1996; 59: 12–5.
4. Стаховская Л.В., Чекнева Н.С. Нимотоп С в лечении цереброва-
скулярной патологии. Метод. рекоменд. Под ред. Л.Г.Ерохиной. М.,
РГМУ, 1995.
5. Яхно Н.Н. Когнитивные расстройства в неврологической кли-
нике. Невролог. журн. 2006; 11 (Прилож. 1): 4–12.
6. Alborch E, Salom JB, Torregrosa G. Calcium channels in cerebral
arteries. Pharmacol Ther 1995; 68: 1–34.
7. Almkvist O, Winblad B. Early diagnosis of Alzheimer dementia based
on clinical and biological factors. Eur Arch Psychiat Clin Neurosci 1999;
249 (Suppl. 3): III/3–III/9.
8. Avery RB, Johnston D. Multiple channel types contribute to the lowvoltage-
activated calcium current in hippocampal CA3 pyramidal
neurons. J Neurosci 1996; 16: 5567–82.
9. Bakker FC, Klijn CJM, Jennekens-Schinkel A et al. Cognitive impairment
in patients with carotid artery occlusion and ipsilateral transient
ischemic attacks. J Neurol 2003; 250: 1340–7.
10. Ballard C, Rowan E, Stephens S et al. Prospective follow-up study
between 3 and 15 months after stroke: Improvements and decline in
cognitive function among dementia-free stroke survivors >75 years of
age. Stroke 2003; 34: 2440–4.
11. Ban TA, Morey L, Aguglia E et al. Nimodipine in the treatment of old
age dementias. Prog Neuropsychol Pharmacol Biol Psych 1990; 14:
350–9.
12. Bennett DA, Wilson RS, Schneider JA et al. Natural history of mild
cognitive impairment in older persons. Neurology 2002; 59: 198–205.
13. Campbell LW, Hao SY, Thibault O et al. Aging changes in voltagegated
calcium currents in hippocampal CA1 neurons. J Neurosci 1996;
16: 6286–95.
14. Collie A, Maruff P. An analysis of systems of classifying mild cognitive
impairment in older people. Austral New Zealand J Psychiat 2002; 36:
133–40.
15. Correia S, Brennan-Krohn T, Schlicting E et al. Diffusion-tensor
imaging in vascular cognitive impairment and mild cognitive impairment:
relationship with executive functioning. In: 2nd Congress of the
International Society for Vascular Behavioural and Cognitive Disorders
(Vas-Cog). Abstract book. Florence, 2005; 88.
16. De Riu PL, Demontis MP, Anania V et al. Brain electrobiogenesis protection
induced by nimodipine and MK-801 during acute hypoxia in
hypertensive rats. Pharmacol Res 1995; 31: 169–73.
17. Drzezga A, Lautenschlager N, Siebner H et al. Cerebral metabolic
changes accompanying conversion of mild cognitive impairment into
Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging
2003; 30: 1104–13.
18. Elias MF, Beiser A, Wolf PA et al. 22-years of prospective study of the
preclinical phase of Alzheimer’s disease: The Framingham cohort. In:
Research and Practice in Alzheimer’s Disease. Vol. 5. Ed. By B.Vellas et al.
Paris: Serdi Publisher, 2001; 50–6.
19. Frisoni GB, Galluzzi S, Bresciani L et al. Mild cognitive impairment
with subcortical vascular features. Clinical characteristics and outcome.
J Neurol 2002; 249: 1423–32.
20. Garibotto V, Borroni B, Kalbe E et al. Education and occupation as
proxies for reserve in aMCI converters and AD: FDG-PET evidence.
Neurology 2008; 71: 1342–9.
21. Geroldi C, Ferrucci L, Bandinelli S et al. Mild cognitive deterioration
with subcortical features: Prevalence, clinical characteristics, and association
with cardiovascular risk factors in community-dwelling older
persons (The InCHIANTI Study). J Am Ger Soc 2003; 51: 1064–71.
22. Grobe-Einsler R. Clinical aspects of nimodipine. Neurobiol Aging
1993; 13: S39–45.
23. Hauerberg J, Rasmussen G, Juhler M, Gjerris F. The effect of nimodipine
on autoregulation of cerebral blood flow after subarachnoid haemorrhage
in rat. Acta Neurochir (Wien) 1995; 132: 98–103.
24. Herz RC, De Wildt DJ, Versteeg DH. The effects of gamma 2-
melanocyte-stimulating hormone and nimodipine on cortical blood
flow and infarction volume in two rat models of middle cerebral artery
occlusion. Eur J Pharmacol 1996; 306: 113–21.
25. Jackson CE, Snyder PJ. Electroencephalography and event-related
potentials as biomarkers of mild cognitive impairment and mild
Alzheimer’s disease. Alzheimer’s & Dementia 2008; 4 (suppl.):
S137–S143.
26. Josten-Weyn Banningh LWA, Kessels RPC, Rikkert MGM et al. A cognitive
behavioural group therapy for patients diagnosed with mild cognitive
impairment and their significant others: feasibility and preliminary
results. Clin Rehabil 2008; 22: 731–40.
27. Kabuto H, Yokoi I, Mori A. Neurochemical changes related to ageing
in the senescence-accelerated mouse brain and the effect of chronic
administration of nimodipine. Mech Ageing Dev 1995; 80: 1–9.
28. Kanowski S, Fischhov P, Hiersemenzel R et al. Therapeutic efficacy of
nootropic drugs – a discussion of clinical phase III studies with
nimodipine as a model. In: Diagnosis and treatment of senile dementia.
M.Bergener, B.Reisberg (Eds.). Berlin etc.: Springer-Verlag. 1989;
339–49.
29. Kivipelto M, Helkala E-L, Hanninen T et al. Midlife vascular risk factors
and late-life mild cognitive impairment. A population-based study.
Neurology 2001; 56: 1683–9.
30. Knopman DS. Treatment of mild cognitive impairment and
prospects for prevention of Alzheimer's disease. In: Mild Cognitive
Impairment: Aging to Alzheimer's Disease. Ed. by R.C.Petersen. Oxford:
Oxford University Press, 2003; 243–58.
31. Korenkov AI, Pahnke J, Frei K et al. Treatment with nimodipine or
mannitol reduces programmed cell death and infarct size following
focal cerebral ischemia. Neurosurg Rev 2000; 23: 145–50.
32. Levere TE, Walker A. Old age and cognition enhancement of recent
memory in aged rats by the calcium channel blocker nimodipine. Neurobiol
Aging 1991; 13: 63–6.
33. Londos E, Boschian K, Linden A et al. Effects of a goal-oriented rehabilitation
program in mild cognitive impairment: a pilot study. Am J
Alzheimers Dis Other Demen 2008; 23: 177–83.
34. Lopez-Arrieta J. Nimodipine. In: Evidence-based Dementia Practice.
Ed. by N.Qizilbash et al. Oxford: Blackwell Science, 2002; 537–40.
35. Louis ED, Schupf N, Manly J et al. Association between mild parkinsonian
signs and mild cognitive impairment in a community. Neurology
2005; 64: 1157–61.
36. Luis CA, Loewenstein DA, Acevedo A et al. Mild cognitive impairment:
Directions for future research. Neurology 2003; 61: 438–44.
37. Lustig HS, Ahern KB, Greenberg DA. Omega-agatoxin IVA and excitotoxicity
in cortical neuronal cultures. Neurosci Lett 1996; 213: 142–4.
38. Meguro K, Ishii H, Yamaguchi S et al. Is Vascular Cognitive Impairment
the preclinical stage of Vascular Dementia: The Tajiri Project. In:
2nd Congress of the International Society for Vascular Behavioural and
Cognitive Disorders (Vas-Cog). Abstract book. Florence, 2005; 71.
39. Nomura M. Effect of nimodipine on brightness discrimination learning
test in Wistar Kyoto and spontaneously hypertensive rats. Drugs Res
1988; 38: 1282–6.
40. Nordlung A, Rolstad S, Klang O et al. Mild Cognitive Impairment of
primary and vascular aetiology: AD and VaD in their preliminary
stages? In: 2nd Congress of the International Society for Vascular
Behavioural and Cognitive Disorders (Vas-Cog). Abstract book. Florence,
2005; 33.
41. Noskovic P, Faberova V, Fabianova M. Effect of a combination of
pentoxifylline and nimodipine on lipid peroxidation in postischemic
rat brain. Mol Chem Neuropathol 1995; 25: 97–102.
42. Palmer K, Fratiglioni L, Winblad B. What is mild cognitive impairment?
Variations in definitions and evolution of nondemented persons
with cognitive impairment. Acta Neurol Scand 2003; 107 (Suppl. 179):
14–20.
43. Palmer K, Backman L, Winblad B, Fratiglioni L. Detection of
Alzheimer's disease and dementia in the preclinical phase: population
based cohort study. Brit Med J 2003; 326: 245–9.
44. Petersen RC. Mild cognitive impairment: transition from aging to
Alzheimer’s disease. In: Alzheimer’s Disease: Advances in Etiology,
Pathogenesis and Therapeutics. Ed. by K.Iqbal et al. Chichester etc.:
Wiley, 2001; 140–51.
45. Petersen RC, Smith GE, Waring SC et al. Mild cognitive impairment:
clinical characterization and outcome. Arch Neurol 1999; 56: 303–8.
46. Petersen RC, Stevens JC, Ganguli M et al. Practice parameter: Early
detection of dementia: Mild cognitive impairment (an evidence-based
review). Report of the Quality Standards Subcommittee of the American
Academy of Neurology. Neurology 2001; 56: 1133–42.
47. Petersen RC, Doody R, Kurz A et al. Current concepts in mild cognitive
impairment. Arch Neurol 2001; 58: 1985–92.
48. Reisberg B, Prichep L, Mosconi L et al. The pre-mild cognitive
impairment, subjective cognitive impairment stage of Alzheimer’s disease.
Alzheimer’s & Dementia 2008; 4 (suppl.): S98–108.
49. Sandin M, Jasmin S, Levere T. Aging and cognition. Facilitation of
recent memory in aged nonhuman primates by nimodipine. Neurobiol
Aging 1990; 11: 573–5.
50. Scriabine A. Pharmacology overview: Nimodipine in CNS indications.
In: Nimodipine: Pharmacological and clinical results in cerebral
ischemia. A.Scriabine et al (Eds.). Berlin etc.: Springer-Verlag, 1991; 1–7.
51. Skoog I. Prevalence of probable AD, AD w/CVD, and probable VaD:
«Pure» is not the norm. In: 2nd Congress of the International Society for
Vascular Behavioural and Cognitive Disorders (Vas-Cog). Abstract book.
Florence, 2005; 11.
52. Small GW. What we need to know about age related memory loss.
Brit Med J 2002; 324: 1502–5.
53. Small BJ, Mobly JL, Jonsson Laukka E et al. Cognitive deficits in preclinical
Alzheimer’s disease. Acta Neurol Scand 2003; 107 (Suppl. 179):
29–33.
54. Stephens S, Kenny RA, Rowan E et al. Association between mild vascular
cognitive impairment and impaired activities of daily living in
older stroke survivors without dementia. J Am Ger Soc 2005; 53 (1):
103–7.
55. Viveros MP, Martin S, Ormazabal M et al. Effects of nimodipine and
nifedipine upon behavior and regional brain monoamines in the rat.
Psychopharmacology (Berl.) 1996; 127: 123–32.
56. Wahlund LO, Pihlstrand E, Eriksdotter Jonhagen M. Mild cognitive
impairment: experience from a memory clinic. Acta Neurol Scand
2003; 107 (Suppl. 179): 21–4.
57. Waite LM, Broe GA, Grayson DA, Creasey H. Preclinical syndromes
predict dementia: the Sydney older persons study. J Neurol Neurosurg
Psychiat 2001; 71: 296–302.
58. Wolf H, Jelic V, Gertz H-J et al. A critical discussion of the role of neuroimaging
in mild cognitive impairment. Acta Neurol Scand 2003; 107
(Suppl. 179): 52–76.